Clinical Trial: The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal Threshold

U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07683442) titled 'The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal Threshold' on June 26.

Brief Summary: The goal of this clinical trial is to investigate the 1-month treatment effects of different dose of lemborexant in moderate OSA adult patients (18-65 years of age) with low arousal threshold.

The main questions it aims to answer are:

Primary outcome measure: Apnea/hypopnea index (AHI)

Secondary outcome measure:

1. Polysomnography parameters

* Mean and nadir oxygen saturation

* Sleep efficiency

* Wake after sleep onset (WASO)

* Sleep latency

* Rapid eye movement (REM) latency...